Drug intelligence / Profile preview

CC-101

Development stage: Phase 2
Lead developer: Clarion Cells
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

CC-101 (formerly NR1) is an investigational allogeneic neural stem cell therapy developed by Clarion Cells for the treatment of chronic ischemic stroke. The therapy consists of neural stem cells administered via stereotactic intracerebral transplantation into the brain tissue immediately adjacent to a prior stroke lesion. The primary therapeutic objective is to facilitate neural repair and promote motor function recovery in patients with persistent motor impairment following a stroke. CC-101 is currently being evaluated in the Phase 2b suNR1se II clinical trial, which also investigates the role of short-term immunosuppression with tacrolimus to support cell survival and integration.

Other names: allogeneic neural stem cells

Beyond the preview

Go deeper on CC-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-101.

Explore the full profile